Figure 5
Knockdown of PTPRK expression in EBV-negative KM-H2 cells increases the growth and survival of HL cells. (A) Semiquantitative RT-PCR for PTPRK mRNA (top) and immunoblotting for PTPRK protein (bottom) following siRNA-mediated knockdown of PTPRK expression in EBV-negative KM-H2 cells. (B) Cell viability (trypan blue; left) and cell proliferation (WST-1; right) assays on KM-H2 cells following treatment with PTPRK-specific siRNA. The down-regulation of PTPRK expression in these cells results in a significant increase in cell viability and proliferation (* denotes significant difference; P values are .02 for viability and .003 for proliferation). Transfection with irrelevant siRNA oligonucleotides had no effect on PTPRK expression, cell viability, or proliferation (data not shown).

Knockdown of PTPRK expression in EBV-negative KM-H2 cells increases the growth and survival of HL cells. (A) Semiquantitative RT-PCR for PTPRK mRNA (top) and immunoblotting for PTPRK protein (bottom) following siRNA-mediated knockdown of PTPRK expression in EBV-negative KM-H2 cells. (B) Cell viability (trypan blue; left) and cell proliferation (WST-1; right) assays on KM-H2 cells following treatment with PTPRK-specific siRNA. The down-regulation of PTPRK expression in these cells results in a significant increase in cell viability and proliferation (* denotes significant difference; P values are .02 for viability and .003 for proliferation). Transfection with irrelevant siRNA oligonucleotides had no effect on PTPRK expression, cell viability, or proliferation (data not shown).

Close Modal

or Create an Account

Close Modal
Close Modal